Last reviewed · How we verify
CPL-01
CPL-01 is a small molecule that targets the SGLT2 receptor.
CPL-01 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | CPL-01 |
|---|---|
| Also known as | Infiltration of study drug |
| Sponsor | Cali Pharmaceuticals LLC |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, CPL-01 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Diarrhea
- Vomiting
Key clinical trials
- Phase 3 Bunionectomy Study (PHASE3)
- CPL-01 in the Management of Postoperative Pain After Bunionectomy (PHASE3)
- Herniorrhaphy for Postoperative Pain (PHASE3)
- Post-Operative Pain and Opioid Reduction Trial After Bunionectomy (PHASE2)
- Evaluate the Safety and Pharmacokinetic Profile of CPL-01 in the Management of Acute Postoperative Pain (PHASE2)
- A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CPL-01 CI brief — competitive landscape report
- CPL-01 updates RSS · CI watch RSS
- Cali Pharmaceuticals LLC portfolio CI